Treatment of C3H/HeJ grafted mice with baricitinib [prevention]. Mus musculus

The C3H/HeJ grafted model of alopecia areata was used to determine the efficacy of systemic baricitinib at preventing alopecia or treating established disease. The efficacy of topical baricitinib at treating established alopecia in the C3H/HeJ grafted model was also assessed. Microarrays were performed on skin RNA at week 0 and week 12 after starting treatment in all models. Overall design: Baricitinib was administered in systemic form at the time of grafting. Skin samples were taken after 12 weeks.

本研究采用斑秃（alopecia areata）C3H/HeJ移植模型，旨在评估全身给药的巴瑞替尼（baricitinib）预防斑秃发作或治疗已发生斑秃的疗效。同时，本研究也评估了局部外用巴瑞替尼在该C3H/HeJ移植模型中治疗已出现斑秃的效果。针对所有实验模型，我们在治疗启动后的第0周及第12周采集皮肤RNA，并开展微阵列（Microarrays）检测。整体实验设计：于移植造模时给予全身给药形式的巴瑞替尼，并在造模12周后采集皮肤样本。